TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90α/uPA/MMP2 signaling pathway

Kai Liu†, Shao-Hua Xu†, Zhao Chen, Qing-Xin Zeng, Zhi-Jun Li* and Zhou-Miao Chen*

Abstract

Background: Waixenicin A, a bioactive extract of soft coral Sarcothelia edmondsoni, has been shown to be anti-neoplastic. However, its mechanisms of action remain unclear. Cancer stem cells (CSCs) and associated stemness factors are implicated in lung cancer. Here, we investigated the role of Waixenicin A on CSCs-like and metastatic lung cancer cells.

Methods: We demonstrated and compared TRPM7 expression in the non-tumor lung tissues or bronchial epithelial 16-HBE cell line. TRPM7 was aberrantly expressed in the cancer tissues and SPCA-1, NCI-H520, SK-MES-1, A549 and 95D cell lines.

Results: Increased TRPM7 expression was associated with enhanced SOX2, KLF4, and CD133, Hsp90α, uPA, and MMP2 expression in lung cancer cells. TRPM7-silencing inhibited epithelial-to-mesenchymal transition (EMT), suppressed stemness markers and phenotypes, concomitantly suppressed Hsp90α/uPA/MMP2 axis. Coincidently, Waixenicin A treatment downregulated TRPM7 and oncogenic markers; Waixenicin A also attenuated the ability of lung cancer cells to form tumorspheres, in vitro. In validation, our clinicopathological analyses showed that a higher TRPM7 expression was positively correlated with the larger tumor size ($p = 0.007$), positive lymph node metastasis ($p = 0.005$) and disease grade ($p = 0.003$).

Conclusions: Through its ability to inhibit Hsp90α/uPA/MMP2 signaling and suppress TRPM7 expression, we showed that Waixenicin A is a potential anticancer therapeutic agent for treating malignant lung cancer.

Keywords: Lung Cancer, TRPM7, Waixenicin A, cancer stem cells.

Research highlights

1. TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes
2. TRPM7 modulation of the Hsp90α/uPA/MMP2 signaling pathway
3. Waixenicin A is a potential anticancer therapeutic agent with TRPM7 modulation efficacy

Background

Lung cancer, with an estimated incidence of 1.8 million cases and constituting approximately 13% of all new cancer diagnoses, is the most common malignancy and the leading cause of cancer-related deaths, globally [1]. With a high fatality of 0.87 as estimated by the overall mortality to incidence ratio, and a relatively low 5-year survival rate of 17.8%, lung cancer has one of the poorest prognoses among all cancers [2]. With less than 40% of lung cancer patients being eligible for surgical resection due to late/advanced stage presentation, prognosis remains poor, as many patients do not survive regardless of chemo- and/or radio-therapy, and early metastases with high recurrence rate continue to plague therapeutic
efforts [3], thus, necessitating the discovery or development of more effective therapeutic strategies to limit chemoresistance, inhibit formation of micrometastases and prevent disease recurrence.

In the last decade, the role of cancer stem cells (CSCs) in the causation of chemotherapy failure and their therapeutic implication as potential targets for prevention of malignancies, including lung cancer has garnered increased interest. The lung CSCs model suggest that the malignant phenotype of lung cancer cells is sustained by a sub-population of cells with enhanced capacity for self-renewal, differentiation and intrinsic resistance to contemporary chemotherapy and radiation. These CSCs are increasingly implicated in disease recurrence after definitive therapy and functionally associated with minimal residual disease [4, 5], especially as it has been suggested that conventional chemotherapeutic strategies mainly target proliferating cells, while the CSCs remain untouched by manipulating the multidrug resistant mechanisms, thereby facilitating the relapse of cancer [6]. The delivery or administration of drugs that target and eliminate CSCs may constitute a more efficient therapeutic strategy in the treatment of patients with recurrent or advanced stage lung cancer [7, 8]. For this reason, drugs that selectively target CSCs offer a greater promise for cancer therapy and prevention.

Evidence continue to accumulate that dietary phytochemicals or plant extracts possess cancer preventive and/or limiting potential, as demonstrated by their ability to eliminate transformed/malignant cells through various anti-cancer mechanisms, in vitro and in vivo tumor xenograft models [9]; more so, some phytochemicals have demonstrated the ability to target CSCs by modulating genes and signaling pathways that facilitate the self-renewal capacity of CSCs and their associated drug resistance [10, 11].

Recent studies continue to outline the involvement of intracellular ion channels such as potassium or sodium channels in cancer development and progression, especially with their aberrant expression in malignancies and contribution in cellular proliferation, evasion of cell death, metabolic reprogramming, neovascularization, and enhanced motility of tumor cells [12, 13]. However, aside their possession of an ion channel and functional α-kinase domain, as well as their implication in Mg\(^{2+}\) homeostasis, the role of non-selective cation Transient Receptor Potential (TRP) channels in human lung cancer remains underexplored. The TRP superfamily currently consist of 28 mammalian members divided into 6 subgroups based on the homology of their sequence, namely ankyrin-like (TRPA), canonical (TRPC 1–7), polycystin (TRPP 1–5), mucolipin (TRPML 1–3), vaniloid (TRPV 1–6), and melastatin (TRPM 1–8) [14]. Unlike TRPM1 that plays the role of a tumor suppressor gene in melanoma, TRPM7 and TRPM8 are aberrantly expressed in pancreatic, gastric, breast and human head and neck cancers [15, 16]. Moreover, TRPM7 has been shown to regulate CSCs in glioma by modulating Notch and STAT3 signaling pathways [17, 18], however, it’s probable role in the modulation of lung cancer stem cells, induction of metastatic and drug-resistant phenotypes, its facilitation of poor prognosis, and likely targetability by therapeutic agents are unexplored in lung cancer patients and serve as the subject of our present study. Waixenicin A is a bioactive organic extract of the soft coral Sarcothelia edmondsoni (otherwise known as Anthellia edmondsoni), which has been shown to effectively inhibit TRPM7-mediated Mn\(^{2+}\) influx at concentrations as low as 30 μg/mL [16], modulate intestinal motility and regulate the pathophysiology of human gastric and breast adenocarcinoma cells [19]. Thus, in the present study, we investigated the probable role of TRPM7 in the modulation of lung cancer stem cells, induction of metastatic and drug-resistant phenotypes, and its facilitation of poor prognosis, as well as the inhibitory role of Waixenicin A on likely TRPM7-mediated CSCs-like and metastatic phenotypes of malignant lung cells.

**Methods**

**Drugs and reagents**

Waixenicin A was obtained from Huienna Chemical Export and Import Company (Tian Jin, China), Cisplatin (≥ 99.9% trace metal basis, 479,306 ALDRICH, Sigma-Aldrich, CA, USA) and Doxorubicin (≥ 98% HPLC, Sigma-Aldrich, CA, USA) were suspended in DMSO, prepared at a stock concentration of 1 mg/ml and stored at 20°C.

**Cell lines and cell culture**

Two NSCLC adenocarcinoma cell lines (SPCA-1 and A549) and two NSCLC squamous carcinomas cell lines (NCI-H520 and SK-MES-1) and one lung giant cell carcinoma cell line (95D) as well as SV40-immortalized human bronchial epithelial 16-HBE cell line were purchased from the Chinese Academy of Sciences Cell Bank and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine 100 U/ml penicillin and 100 μg/ml streptomycin (Thermo Fisher Scientific, Inc. Waltham, Ma, USA) in a 5% CO\(_2\) humidified atmosphere at 37°C. Cultured cells were passaged ≥98% confluence or media changed every 72 h.

**Sulforhodamine B colorimetric cell viability assay**

1 × 10\(^5\) cells/ml A549 or 95D cells were plated per well containing 200 μl medium in 96-well culture plates overnight, then the cells were treated with different concentrations of Waixenicin A for 12–72 h, similarly, cells were treated with 0–20 μM Cisplatin or Doxorubicin for 48 h. Cell viability was examined at specified concentrations of
named drugs. After exposure to treatment, cell viability was estimated using the sulforhodamine B assay as previously described [20]. Each experiment was performed at least three times in triplicate, and results are expressed as the mean ± SD.

Western blot analysis
25 μg of total cell lysates were subjected to a 10% polyacrylamide sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) and blots transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were then incubated with 5% non-fat milk in PBS with Tween-20 for 1 h to exclude non-specific binding before incubation overnight at 4°C in specific primary antibodies against TRPM7, Vimentin, p21, Bak1, SOX2, KLF4, CD133, HSP90α, uPA, MMP2, Survivin, and STAT3 (Santa Cruz Biotechnology, CA, USA) followed by incubation in peroxidase - conjugated secondary antibody at room temperature for 1 h, washed with PBST three times, then the protein signals were observed using the UVP BioSpectrum system (Analytic Jena Company).

Big data analysis
TRPM7 gene expression data in lung large-cell carcinoma (LCC), adenocarcinoma (ADC), squamous cell cancer (SCC) and normal lung tissue were accessed via the Gene Expression Omnibus (GEO) dataset browser using the series accession number GSE19188.

Quantitative real-time PCR
The RNA expression levels in the treated and untreated control lung cancer cells were measured using a RT-PCR system. After extraction of total RNA using TRIzol reagent (Invitrogen, Thermo Fisher Scientific Inc., Carlsbad, CA, USA), 1 μg of the total RNA was reverse-transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Germantown, MD, USA). The amplified mRNA level of each specific stemness gene was normalized to that of GAPDH. All procedure was performed following manufacturers’ instruction.

Small-interfering RNA transfection
The shRNA sequence targeting TRPM7 gene was F: 5’-AATGATATAAAGGTGCCAGTT-3’, R: 5’-GAAA AAAGGCACCTTTATAATCATATTAAATT CAAGAGATT AATGATATAAAGGTGCCCTTTTCC’3’,  and 2 μL warm StemXVivo serum-free tumorsphere media (CCM012, R&D Systems, Minneapolis, MN, USA) supplemented with 2 U/mL heparin (Sigma) and 0.5 μg/mL hydrocortisone (Sigma) following the manufacturer’s protocol, and cells incubated in 5% CO2 incubator, at 37°C for 7–10 days. Tumor spheres were then observed under microscope and those larger than 50 μm counted.

Tumor sphere formation assay
We generated tumorspheres by seeding 1 × 104 control 95D cells or knockdown clones (shTRPM7 clones 1 and 2) per well in ultra-low adhesion 6-well plates, containing 2 mL warm StemXVivo serum-free tumorsphere media (CCM012, R&D Systems, Minneapolis, MN, USA) supplemented with 2 U/mL heparin (Sigma) and 0.5 μg/mL hydrocortisone (Sigma) following the manufacturer’s protocol, and cells incubated in 5% CO2 incubator, at 37°C for 10 days. Tumor spheres were then observed under microscope and those larger than 50 μm counted.

Colonies formation assay
For anchorage-independent growth, 1 × 103 A549 or 95D control cells or TRPM7 knockdown clones were suspended per ml in 2 ml of 0.3% agar with 1% N2 Supplement (Invitrogen), 2% B27 Supplement (Invitrogen), 20 ng/ml human platelet growth factor (Sigma-Aldrich), 100 ng/ml epidermal growth factor (Invitrogen) and 1% antibiotic-antimycotic (Invitrogen) overlaid into 6-well plates containing a 0.5% agar base. Formed colonies were stained with 2% crystal violet on day 21, then colonies ≥0.2 mm in diameter were observed and counted under microscope.

Side-population identification assay
For identification of SP cells, 1 × 106 95D control cells or TRPM7 knockdown clones were incubated in 5 μg/mL Hoechst 33342 dye (Molecular Probes, Thermo Fisher Scientific) for 90 min with or without 50 μM verapamil. Cell samples were analyzed and sorted using a BD FACSAria™ III cell sorter (BD Biosciences) and SUMMIT software for data acquisition and analysis. Fluorescence emission was collected with a 405/30 nm and 670/40 nm band pass filter for Hoechst blue and Hoechst red, respectively. Dead cells were excluded using propidium iodide fluorescence at 670/30 nm.

Transwell Matrigel invasion assay
Evaluation of the invasive capacity of A549 or 95D cells was performed using Transwell Filter (8 μm pore size, Corning Costar Corporation, Cambridge, MA) with Matrigel (BD Biosciences). Control cells or TRPM7-knockdown clones were plated in the upper chamber containing 200 μL serum-free culture medium, while the bottom chambers contained 500 μL of complete culture medium. After incubation for 24 h, the non-invaded cells in the upper chamber were carefully removed with cotton swap, and the invaded cells in the membrane of the lower chambers were stained with Giemsa stain. The stained cells were observed, photographed and counted under microscope in at least 5 randomly-selected fields.
**Transwell migration assay**

For the cell migration assay, Transwell membranes (8 μm pore size, 6.5 mm diameter, Corning Costar Corporation, Cambridge, MA) were used. 5 x 10^5 A549 or 95D cells were collected, washed, and re-suspended in serum-free medium in the upper chambers, while the lower chamber wells contained complete culture medium. After incubation for 24 h, the cells remaining on the upper membrane were carefully removed with cotton swap, while the migrated cells in the membrane of the lower chamber were fixed with 95% ethanol and stained with 0.1% crystal violet. 5 fields were randomly selected, and images captured under microscope at a magnification of ×200. Experiments were performed 3 times in triplicate.

**Immunofluorescence assay**

Human lung cancer cells were fixed in 10% paraformaldehyde for 30 min, blocked with goat serum for 30 min, then incubated with anti-TRPM7 and anti-SOX2 antibodies (Santa Cruz Biotechnology) at a dilution of 1:100 for 1 h at 37 °C. Cells were washed 3 times with PBS, incubated with conjugated fluorescence isothiocyanate (FITC) for 1 h at 37 °C. DAPI was used for nuclear staining. The fluorescence intensity and cellular localization were evaluated under fluorescent microscope.

**Statistical analyses**

SPSS v.18.0 for Windows software (SPSS Inc. Chicago, IL, USA) was used for statistical analysis. All data are expressed as mean ± SEM of experiments performed independently at least twice in triplicate. One-way ANOVA and student’s t- test were used to determine the statistical differences between treatment groups. A p value < 0.05 was considered statistically significant.

**Results**

**TRPM7 is aberrantly expressed in lung cancer tissue samples and cell lines**

To understand the role of TRPM7 in lung cancer, we analyzed the differential expression profile of TRPM7 in paired lung adenocarcinoma or squamous cell lung carcinoma and adjacent normal alveoli tissue samples from our lung cancer cohort, using immunohistochemical (IHC) staining. Analysis of our data revealed that compared with the null or weak TRPM7 expression in normal alveoli samples, TRPM7 was strongly expressed in lung adenocarcinoma or squamous cell lung carcinoma (Fig. 1a). This IHC finding was corroborated by western blot analyses showing significantly enhanced TRPM7 protein expression level in lung tumor (T) compared to the adjacent non-tumor (NT) tissues (3.4-fold, p < 0.01) (Fig. 1b). Similarly, while TRPM7 protein expression was weak in the SV40-immortalized human bronchial epithelial 16-HBE cell line, TRPM7 was moderately expressed in SPCA-1 and NCI-H520, and strongly expressed in the SK-MES-1, A549 and 95D human lung cancer cell lines (Fig. 1c). These data showing aberrantly expressed TRPM7 in lung cancer tissue samples and cell lines are suggestive of the oncogenic role of TRPM7 in lung cancer cells.

**TRPM7 is an independent indicator of poor prognosis in lung cancer**

For a functional characterization of TRPM7 in lung cancer, we accessed and analyzed TRPM7 gene expression profile in early stage NSCLC dataset with the series accession number GSE19188 and consisting of large-cell carcinoma (LCC, n = 19), adenocarcinoma (ADC, n = 45), squamous cell cancer (SCC, n = 27) and normal lung tissue (n = 65) were accessed via the Gene Expression Omnibus (GEO) browser. Consistent with earlier findings, we observed that relative to its expression in normal lung tissue, TRPM7 gene expression in the LCC, ADC and SCC samples was significantly elevated (p < 0.01) (Fig. 2a). Furthermore, TRPM7-specific survival analysis of our lung cancer cohort showed that patients with high expression of TRPM7 exhibited worse cumulative survival than those with low TRPM7 expression (p < 0.001), with a 46.0 and 59.1% difference in survival at third and fifth year, respectively (Fig. 2b and Additional file 1: Figure S1). We also demonstrated that TRPM7 expression positively correlated with tumor stage, as we observed a 1.9-fold, 2.4-fold, and 3.6-fold increase in the expression of TRPM7 in stage II, stage III and stage IV, when compared with its expression in stage I (Fig. 2c and d). These findings not only confirm the oncogenic role of TRPM7 in lung cancer but are indicative of the potential role of TRPM7 as an independent indicator of poor prognosis in lung cancer.

**Downregulation of TRPM7 expression suppresses the viability and metastatic phenotype of human lung cancer cells**

In furtherance of our functional characterization of TRPM7 in lung cancer, we knocked down TRPM7 in A549 or 95D cells using the short hairpin RNA. Our results showed that downregulation of TRPM7 protein expression in the lung cancer cells, was associated with concomitant downregulation of vimentin mRNA expression, while the mRNA expression of E-cadherin, p21 and BAK was upregulated (Fig. 3a). Since p21 is a key regulator of the cell cycle and associated with G1/G2 arrest [21] and BAK serves a pro-apoptotic function [22], rendering both as modulators of cell survival and proliferation, we thus assessed the effect of TRPM7 on the viability and proliferation of lung cancer cells using the SRB cell viability assay. We demonstrated that silencing TRPM7 in A549 or 95D cells significantly suppressed the ability of these cells to form colonies (p < 0.01) (Fig. 3b). We also demonstrated that compared to the control A549 cells, at the 72-h time-point, the shTRPM7 clones 1 and 2 exhibited 2.13-fold and 2.33-fold reduction in viability; similarly,
for the 95D cells, the fold viability difference between control and shTRPM7 clones 1 and 2 was 1.80-fold and 2.00-fold (Fig. 3c). In addition, Silenced TRPM7 expression in lung cancer cells, markedly reduced their migration (~ 4.6-fold, \(p < 0.01\)) and invasion (~ 6.1-fold, \(p < 0.01\)) potential (Fig. 3d). This is corroborated by findings of our clinicopathological analysis showing that high TRPM7 expression positively correlates with lymph node metastasis (\(p = 0.005\)). These data are suggestive of the critical role of TRPM7 in the modulation of epithelial-to-mesenchymal transition (EMT), as well as the viability and metastatic phenotype of human lung cancer cells.

**TRPM7 regulates the CSCs activities of lung cancer cells by modulating the Hsp90α/uPA/MMP2 signaling pathway**

Since lung cancer is a heterogeneous disease with the presence of CSCs being demonstrated in lung cancer and implicated in the metastatic and treatment-resistant phenotype of malignant lung cells (23), we examined if TRPM7 exhibits any modulatory effect on the CSCs-like phenotype of lung cancer cells and their associated aggressiveness, by evaluating the effect of TRPM7 on the protein expression of stemness markers. Results of our RT-PCR analysis demonstrate that the expression level of TRPM7 mRNA was elevated in tumor-spheres derived from 95D cells, compared to the control 95D cells, and this enhanced expression of TRPM7 was associated with concomitant upregulation of SOX2, CD133, KLF4, heat-shock protein 90α (HSP90α), urokinase plasminogen activator (uPA), and matrix metalloproteinase 2 (MMP2) (Fig. 4a). In addition, we demonstrated that a correlation exists between TRPM7 expression, as TRPM7-expressing 95D cells readily formed tumorspheres, while the TRPM7 knockdown clones significantly lost their ability to form tumorspheres; furthermore, loss of tumorsphere formation ability was associated with...
significant reduction in TRPM7, HSP90α, uPA, and MMP2 mRNA expression level (Fig. 4b). In similar experiments, using immunofluorescence staining, we showed that compared to the small tumorspheres formed by the shTRPM7 clones, tumorspheres derived from the control 95D cells were significantly larger in size, and were characterized by the nuclear co-localization of TRPM7 and SOX2, unlike the shTRPM7 tumorspheres (Fig. 4c). To further explore the effect of TRPM7 in the maintenance of CSCs-like lung SP cells, the human lung cancer cell line 95D was sorted by flow cytometry after incubation with Hoechst 33342 for 90 min. SP cells represented 4.2% of the total 95D control cells, while for the shTRPM7 clone, the SP cells were significantly reduced to only 0.2%. When preincubated with verapamil for 30 min, the proportion of SP cells was reduced to 0.5% of the total 95D control cells, or 0.1% for the shTRPM7 cells (Fig. 4d). These data suggest an association between the observed enhanced tumorsphere formation ability, increased expression of stemness markers, and upregulated TRPM7 expression, as well as indicate that TRPM7 regulates the CSCs activities of lung cancer cells by modulating the Hsp90α/uPA/MMP2 signaling pathway.

TRPM7 inhibitor, Waixenicin A suppresses the CSCs phenotype of lung cancer cells

Having shown that TRPM7 expression is relevant in the pathogenesis and prognosis of lung cancer, as well as inhibitory effects of TRPM7 knockdown in lung cancer cells, we then investigate the effect of TRPM7 inhibitor, Waixenicin A (Fig. 5a) on the TRPM7-rich 95D cells. Our results demonstrate that 48 h treatment of the 95D cells with 5 μM or 10 μM Waixenicin A significantly and dose-dependently inhibited the expression level of TRPM7, Vimentin, Survivin, STAT3, HSP90α, uPA, and MMP2 proteins, compared to the untreated control cells (Fig. 5b). In parallel experiments
using the tumorsphere formation assay, we demonstrated that like the inhibitory effect of shTRPM7 on tumorsphere formation, Waixenicin A not only more efficiently suppressed tumorsphere formation by the lung cancer cells, but also enhanced the anti-CSCs effect of shTRPM7 (Fig. 5c and d). These results are indicative of the molecular and therapeutic targetability of TRPM7 in lung cancer, as well as further corroborate the anti-CSCs effect of targeting TRPM7 in lung cancer cells.

**Discussion**

Despite the significant progress made in anticancer therapy, lung cancer remains as the leading cause of cancer-related deaths in the United States, with a 5-year survival rate of 18.1% and a 25.9% death rate in 2017 (https://seer.cancer.gov/statfacts/html/lungb.html), remains a lethal medical challenge, especially as patients continue to be beleaguered with treatment failure, resistance to therapy and increased incidence of locally advanced and metastatic disease, which are not unrelated with the presence of a small population of lung cancer cells termed CSCs which are characterized by enhanced EMT/metastatic phenotype, facilitate tumor formation, growth and progression [23]. Thus, the needs for the discovery and development of therapeutic strategies that target these lung CSCs effectively.

In the present study, we provide evidence that, TRPM7 (i) is aberrantly expressed in lung cancer tissue samples and cell lines, (ii) is an independent indicator of poor prognosis in lung cancer, and (iii) regulates the CSCs activities of lung cancer cells by modulating the Hsp90α/uPA/MMP2 signaling pathway, while its molecular or therapeutic inhibition (iv) suppresses the viability as well as metastatic and CSCs phenotypes of human lung cancer cells, and (vi) enhances the anticancer effect of standard chemotherapeutics.

Ion channels continue to be implicated in cancer development and progression, being aberrantly expressed...
in tumor tissues or cell lines compared to normal tissues or cells, and are actively involved in cellular proliferation, evasion of cell death, metabolic reprogramming, neovascularization, and enhanced motility of tumor cells [12, 13]; interestingly, while the non-selective, cationic TRPM7 channel which mediates both Ca\(^{2+}\) and Mg\(^{2+}\) influx, has been shown to be overexpressed in several human malignancies, including breast, prostrate, pancreatic, and ovarian cancers, its expression profile and role in lung cancer development and progression remained unknown. In this study, we demonstrated that the preferential overexpression of TRPM7 in lung cancer tissues and cell lines is not only statistically significant but also clinically relevant, as it bears poor prognostic implications in patients with lung cancer (Figs. 1 and 2). This is consistent with data from our correlative clinicopathological analysis showing that TRPM7 positively correlated with tumor grade, tumor size and lymph node metastasis; and is corroborated by the findings of Dhennin-Duthile et al. [13], in which several TRPs including TRPM8 and TRPM7 were shown to be overexpressed in human breast cancer epithelial cells and tissues, with strong positive correlation with pathological parameters such as the Scarff-Bloom-Richardson (SBR) grade, Ki67 proliferative index and tumor size.

Furthermore, we showed that shRNA-mediated reduction of TRPM7 expression significantly suppressed the viability of lung cancer cells, attenuated the ability of the malignant cells to form colonies, and impeded their cell migration and invasion; all these were associated with concomitant downregulation of apoptotic marker...
Bak and mesenchymal markers Vimentin, and Snail, as well as upregulation of epithelial marker E-cadherin and tumor suppressor p21 (Fig. 3). Our finding is consistent with demonstrated upregulation of several transcription factors including Snail, Twist, Zeb, and Vimentin in metastatic cells undergoing EMT [24]. EMT itself entails the physiological or pathological conversion of an epithelial cell into an elongated cell with mesenchymal phenotype. Our data indicate that similar to TGF-β, TRPM7 plays a vital role in the activation of Snail, which in turn downregulates E-cadherin and Bak, while upregulating N-cadherin, p21 and Bcl-xl, and this process is involved in EMT. Similarly, our findings are corroborated by documented reversal of EMT status, with associated inhibition of cell proliferation, migration, and invasion, as well as enhanced cell cycle arrest at G0/G1 and apoptosis in human bladder cancer [25]. This TRPM7-associated expression profile is disease-relevant because the migration of cancer cells requires activation of genes necessary for differentiation, impede proliferative activities, induce anti-apoptotic mechanisms, transform the cells from epithelial to mesenchymal phenotype, suppress receptors that facilitate cell-to-cell attachment, degrade cell-to-cell junctions, and enhance cell motility [24].

Furthermore, we showed for the first time that TRPM7 regulates the CSCs activities of lung cancer cells by modulating the Hsp90α/uPA/MMP2 signaling pathway (Fig. 4a-d). Interestingly, among the genes that are regulated by TRPM7, SOX2, CD133 and KLF4 are cancer stemness markers. HSP90α, uPA and MMP mediates cell proinflammation, invasion, metastasis and drug resistance. The altered expression of these genes, as demonstrated in this study, may be reflective of the functional significance of TRPM7 in lung cancer cells, which to a large extent includes the maintenance of the lung cancer stem cell-like phenotypes and the suppression of lung
metastasis. This is consistent with TRPM7’s documented induction role in the upregulation of CSCs markers such as CD133 and ALDH1, as well as promotes the proliferative, metastatic and CSCs-like phenotypes of GBM cells [17]. The uniqueness of TRPM7 lies in the fact that while it encodes an α-kinase domain fused to the ion channel moiety, the kinase and channel domain may be mutually regulated, however although the kinase domain contributes partially to the modulation of the channel sensitivity to Mg2+ and cAMP, it is not required for TRPM7 channel activity. Our results showing that TRPM7-mediated CSCs-like phenotype in lung cancer is modulated by Hsp90α/uPA/MMP2 signaling is therapeutically-relevant and partially consistent with recently demonstrated role of TRPM7 in the regulation of pancreatic cancer cell invasion through the Hsp90α/uPA/MMP2 pathway [26]. Hsp90 is a master regulator of cancer, and many Hsp90 target genes are nodes of oncogenic pathways [27]. By interacting with receptor tyrosine kinases, cytosolic Hsp90 plays vital roles in cell proliferation, differentiation, migration, and cancer progression. HSP90α is the secreted isoform and is associated with MMP2, implicating extracellular Hsp90 in cancer metastasis [28]. We speculate that the extracellular Hsp90 initiates EMT in lung cancer cells by modulating TRPM7 expression and activity. It is also possible that the surface Hsp90 interacts with the extracellular domain of TRPM7; thus, the disruption of this Hsp90/TRPM7 interaction results in the inhibition of cell invasion and associated with altered actin dynamics in the human lung cancer cells. In the context of TRPM7-mediated lung CSCs regulation as we have demonstrated, Hsp90α has been demonstrated to play an essential role in the regulation of pluripotency transcription factors, such as Oct4, Nanog, and Stat3 in mouse embryonic stem cells (ESCs) [29]. Similar to the findings in breast cancer stem cells [30], and consistent with its role in CSCs-derived primary tumor growth, we demonstrated that TRPM7-dependent targeting of highly expressed Hsp90α in lung CSCs inhibits tumoursphere formation, reduces the number of lung cancer SP cells and potentiates the anticancer effect of standard chemotherapeutics such as doxorubicin and cisplatin (Fig. 4a-d).

Recently, Zierler et al. [16] suggested that waixenicin A is a potent and relatively specific inhibitor of TRPM7 ion channels. In this recent study, waixenicin A was found to be a selective inhibitor of the TRPM7 ion channel, and patch-clamp experiments confirmed waixenicin A as a TRPM7 antagonist. However, the inhibitory effects of waixenicin A on TRPM7 are strongly dependent on intracellular Mg2+ concentration. Furthermore, it was also found that the pharmacological inhibition of TRPM7 by waixenicin A caused growth arrest in the G0/G1 phase (16). Our data confirm that Waixenicin A inhibits native TRPM7 currents in both lung cancer cells and its counterpart lung cancer spheres (Fig. 5a-d). These features make waixenicin A an attractive molecular structure for targeting TRPM7-related lung cancer stemness pathophysiology. This is clinically relevant since the most often lung cancer is a probable CSCs - rich and -driven pathology, therefore the preferential targeting and elimination of these CSCs which are implicated in resistance to standard anticancer therapy, metastasis and recurrence, by TRPM7 silencing or Waixenicin A treatment alone or in combination with conventional anticancer therapeutics, constitute a potential right step towards the development of a more efficient anti-cancer therapeutic strategy for treatment of advance staged, metastatic, or recurrent lung cancer.

**Conclusions**

In conclusion, as depicted in our schematic summary (Fig. 6), we have provided evidence that aberrant TRPM7 expression induces the cancer stem cell-like and metastatic phenotypes of lung cancer cells through positive modulation of the Hsp90α/uPA/MMP2 signaling pathways and induction of pluripotency transcription factors. This results in decreased sensitivity of

![Fig. 6 Pictorial Abstract showing that the molecular or therapeutic inhibition of TRPM7 expression and/or activity attenuates the cancer stem cell-like and metastatic phenotypes of lung cancer cells through the modulation of the Hsp90α/uPA/MMP2 signaling pathway](image-url)
lung cancer cells to chemotherapy, enhanced formation of micro-metastases, disease recurrence and invariably poor prognosis. In essence, we showed that targeting TRPM7 inhibits oncogenic activity, disrupts EMT in favor of the benign epithelial phenotype, inhibit cancer metastasis, attenuate cancer stenness, and increase sensitivity to chemotherapy and potentially results in better prognosis for lung cancer patients.

**Additional file**

Additional file 1: Figure S1. TRPM7 is an independent indicator of poor prognosis in lung cancer. (A) Kaplan-Meier analysis of TRPM7 gene expression in GSE37745 lung cancer dataset show patients with low TRPM7 expression had better overall survival than those with high TRPM7 expression. (B) Kaplan-Meier analysis of TRPM7 gene expression in GSE32019 lung cancer dataset show patients with low TRPM7 expression had longer relapse-free survival than those with high TRPM7 expression. (DOCX 184 kb)

**Abbreviations**

CSCs: Cancer stem cells; EMT: Epithelial-to-mesenchymal transition; FITC: Fluorescein isothiocyanate; GEO: Gene Expression Omnibus; HSP90α: Heat-shock protein 90α; MCC: Matrix metalloproteinase 2; PVDF: Polyvinylidene difluoride; SDS-PAGE: Sodium dodecyl sulfate - polyacrylamide gel electrophoresis; TRP: Transient receptor potential; TRPM7: Transient receptor potential melastatin 7; uPA: Urokinase plasminogen activator

**Acknowledgments**

We are forever indebted to the late Prof. Zhou-Miao Chen for his excellent leadership, and also for his financial, scientific and emotional support. We acknowledge Emily Huang for assistance using the flow cytometer. We thank for the technical assistance of Tim Liu and Jenny Chen.

**Funding**

This work was supported by the Ningbo Natural Science Foundation (No.2016A610191). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Authors contribution**

Conceived and designed the study: KL, ZJL, ZMC; Performed the experiments: KL, SHK, ZC, QXZ; Analyzed the data: KL, ZL, ZMC; Wrote the paper: KL, QXZ; Provided reagents, materials, and experimental infrastructure: KL, ZJL, ZMC; All authors read and approved the final version of the manuscript.

**Ethics approval and consent to participate**

All subjects filled a questionnaire including their informed consent. The study was carried out according to the Helsinki Declaration, and the samples were processed under approval of the written consent statement by the Ethical Committee of the Sir Run Run Shaw Hospital, China (SRRSH 2018-010). The cell lines used in the study do not require ethical approval.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–66.
2. U.S. National Institutes of Health. National Cancer Institute. SEER Cancer Statistics Review, 1975–2011. Available at: http://seer.cancer.gov. Accessed from 21 February to 13 March (2018).
3. Dholaria B, Hammond W, Shreaders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016;9(1):138.
4. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: evidence and controversies. Respiriology. 2013;18(5):57–64.
5. Zakaria N, Satar NA, Abu Halim NH, Ngamil SH, Yussoff NM, Lin J, Yahaya BH. Targeting lung Cancer stem cells: research and clinical impacts. Front Oncol. 2017;7:80. https://doi.org/10.3389/fonc.2017.00080.
6. Liu H, Lv L, Yang K. Chemotherapy targeting cancer stem cells. Am J Cancer Res. 2015;5(3):880–93.
7. Mahli S, Gu X. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach. Expert Opin Drug Deliv. 2015;12:1177–201.
8. Shen S, Xia IX, Wang J. Nanomedicine-mediated cancer stem cell therapy. Biomaterials. 2016;74:1–18.
9. Effrth T, Saeed MEM, Mirghani E, Alim A, Yassin Z, Saeed E, et al. Integration of phytochemicals and phytotherapy into cancer precision medicine. Oncotarget. 2017;8(30):30284–304.
10. Scarpa ES, Niffler P. Phytochemicals as innovative therapeutic tools against Cancer stem cells. Int J Mol Sci. 2015;16(7):15727–42.
11. Dandavate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol. 2016;40:41–192–208.
12. Peruzzo R, Basutto L, Szabo I, Leanza L. Impact of intracellular ion channels on cancer development and progression. Eur Biophys J. 2016;45(7):685–707.
13. Dheninin-Duthilleul I, Gautier M, Fasouzi M, Guibert A, Brevet M, Vaudry D, et al. High expression of transient receptor potential channels in human breast carcinoma epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011;28(5):813–22.
14. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011;12(3):218.
15. Wolf FL, Trapani V. Magnesium and its transporters in cancer: a novel paradigm in tumor development. Clin Sci. 2012;123:417–27.
16. Zieler S, Yao G, Zhang Z, Kuo WC, Pörzgen P, Penner R, et al. Waixenicin a inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J Biol Chem. 2011;286(45):39328–35.
17. Liu M, Inoue K, Leng T, Guo S, Xiong ZG. TRPM7 channels regulate glioma stem cell through STAT3 and notch signaling pathways. Cell Signal. 2014; 26(12):2773–81.
18. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the notch pathway. J Biol Chem. 2013;288(45):39617–67.
19. Kim BJ, Nam JH, Kwon YK, So I, Kim SJ. The role of waixenicin as a transient receptor potential melastatin 7 blocker. Basic Clin Pharmacol Toxicol. 2013; 112(2):83–9.
20. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytoxicity screening. Nat Protoc. 2006;1(3):1112–6.
21. Chen A, Huang X, Xue Z, Cao D, Huang K, Chen J, et al. The role of p21 in apoptosis, proliferation, cell cycle arrest, and antioxidant activity in UVB-irradiated human HaCaT keratinocytes. Med Sci Monit Basic Res. 2015;21:86–95.
22. Tran VH, Bartolo R, Westphal D, Altop A, Dewson G,KLuck RM. Bak apoptotic function is not directly regulated by phosphorylation. Cell Death Dis. 2013;4:e452. https://doi.org/10.1038/cddis.2012.191.
23. Singh S, Chellappan S. Lung cancer stem cells: molecular features and therapeutic targets. Mol Asp Med. 2014;39:560–70.
24. Heerboth S, Hosman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:46s. https://doi.org/10.1186/s40669-015-0048-3.
25. Cao R, Meng Z, Liu T, Wang G, Qian G, Cao T, et al. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway. Oncotarget. 2016;7(45):72941–60.
26. Rybarczyk P, Vanlaeys A, Brassart B, Dhennin-Duthille I, Chatelain D, Sevestre H, et al. The transient receptor potential Melastatin 7 channel regulates pancreatic Cancer cell invasion through the Hsp90α/LPA/MMP2 pathway. Neoplasia. 2017;19(4):288–300.

27. McDonald E, Workman P, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem. 2006;6(11):1091–107.

28. Wong DS, Jay DG. Emerging roles of extracellular Hsp90 in Cancer. Adv Cancer Res. 2016;129:141–63.

29. Bradley E, Bieberich E, Mivechi N, Tangpisuthipongsa D, Wang G. Regulation of embryonic stem cell pluripotency by heat shock protein 90. Stem Cells. 2012;30(8):1624–33.

30. Stivarou T, Stellas D, Vartzi G, Thomaidou D, Patsavoudi E. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo. Cancer Biol Ther. 2016;17(8):799–812.